儿童脑肿瘤免疫治疗临床前模型:障碍与前进之路
儿童脑肿瘤是儿童最常见的实体瘤和癌症相关死亡的主要原因,高危肿瘤预后仍差。免疫检查点抑制剂在成人中的成功引发儿科探索,但需建立并选择相关且稳健的临床前儿童高级别脑肿瘤模型。本文回顾影响模型选择的信息,分享开展国际协作研究中的挑战与潜在解决方案。
要点
- 儿童高级别脑肿瘤总体预后仍差,部分归因于缺乏有效疗法。
- 免疫检查点抑制剂在成人中的成功激发儿科研究兴趣。
- 建立并选择相关且稳健的临床前儿童高级别脑肿瘤模型对改善临床结局至关重要。
核心结论
- 改善临床结局需要建立并选择相关且稳健的临床前儿童高级别脑肿瘤模型。
研究设计与样本
- 综述:基于作者开展的国际协作研究(测试免疫检查点抑制剂联合表观遗传修饰剂以增强适应性免疫治疗儿童脑肿瘤)的模型选择经验。
主要发现
- 儿童脑肿瘤是儿童最常见的实体瘤和癌症相关死亡的主要原因。
- 过去几年儿童中枢神经系统肿瘤诊断和治疗有所改善,但许多高级别肿瘤患者总体预后仍差。
- 较低生存率部分归因于缺乏有效疗法。
- 免疫检查点抑制剂在成人中的出现和成功激发了对这些疗法单用或联合其他药物治疗儿科患者效用的研究兴趣。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain tumors are the most common solid tumor in children and the leading cause of cancer-related deaths. Over the last few years, improvements have been made in the diagnosis and treatment of children with Central Nervous System tumors. Unfortunately, for many patients with high-grade tumors, the overall prognosis remains poor. Lower survival rates are partly attributed to the lack of efficacious therapies. The advent and success of immune checkpoint inhibitors (ICIs) in adults have sparked interest in investigating the utility of these therapies alone or in combination with other drug treatments in pediatric patients. However, to achieve improved clinical outcomes, the establishment and selection of relevant and robust preclinical pediatric high-grade brain tumor models is imperative. Here, we review the information that influenced our model selection as we embarked on an international collaborative study to test ICIs in combination with epigenetic modifying agents to enhance adaptive immunity to treat pediatric brain tumors. We also share challenges that we faced and potential solutions.
引用
- Mishra DK, Popovski D, Morris SM, et al. Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward. Neuro Oncol. 2024. PMID: 37713135. doi:10.1093/neuonc/noad170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。